Funding for this research was provided by:
Instituto de Salud Carlos III (PI16/00579 and CP09/00011, PI16-01843, PMP15/00025, PI12/01683)
Text and Data Mining valid from 2019-05-06
Received: 5 February 2019
Accepted: 17 April 2019
First Online: 6 May 2019
Ethics approval and consent to participate
: Written informed consent was obtained from patients for publication of anonymised clinical data.
: Not applicable.
: MH and RM are co-inventors on patent applications filed by Columbia University Medical Center (CUMC) for deoxynucleoside therapy for mitochondrial DNA depletion syndromes including TK2 deficiency. The patent applications and other intellectual property have been licensed by CUMC to Meves Pharmaceuticals, Inc. CUMC may be eligible to receive payments related to the development and commercialization of the technology. Any potential licensing fees earned will be paid to CUMC and are shared with inventors through CUMC distribution policy. MH and RM are paid consultants to Meves Pharmaceutical, Inc. The rest of authors declare that they have no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.